DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the BIO MEDICA LABORATORIES L (BMLL) share price today?

BIO MEDICA LABORATORIES L (BMLL) is trading at ₹139.45 on the NSE, down 0.43% on the day. Source: DocStoX.

What is the PE ratio of BIO MEDICA LABORATORIES L?

BIO MEDICA LABORATORIES L has a price-to-earnings (PE) ratio of 13.1 in the Healthcare sector.

What is the market capitalisation of BIO MEDICA LABORATORIES L?

BIO MEDICA LABORATORIES L has a market capitalisation of approximately ₹170 crore.

BIO MEDICA LABORATORIES L

BMLL·NSE·Healthcare

₹139.45▼ -0.60 (-0.43%)

Healthcare · Pharmaceuticals

Revenue compounding 33% a year

Day₹138.95

₹140.05

52W₹102

₹14882%

Open

₹139.00

High

₹140.05

Low

₹138.95

Prev Close

₹140.05

Volume

21.0K

VWAP

₹139.62

Snapshot

Key fundamentals

Market Cap

₹170 Cr

P/E Ratio

13.08Cheap

P/B Ratio

2.74

EPS

₹10.66

Book Value

₹49.24

ROE

99.50%Strong

ROCE

64.16%Efficient

Dividend Yield

0.00%

Debt / Equity

1.30Elevated

Face Value

₹10.00

52W High

₹148.00

52W Low

₹101.50

Sector

Healthcare

Industry

Pharmaceuticals

Expensive

None moatHigh uncertainty

Fair value estimate

₹109

▼ 21.8%downside

Trading at ₹139 — 22% above our estimate

BearFair valueBull

₹93₹109₹125

/100

Business quality — Solid

Growth 100Profitability 100Efficiency 50Valuation 64

Plain English

Our view

Revenue compounding 33% a year
Strong returns on equity (100%)
Fundamental red flags (Piotroski 1/9)

Strengths

Strong returns on equity (100%)
Capital is working hard (ROCE 64%)
Revenue compounding 33% over 3 years
Profit growing 210% a year

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

Needs a return-on-equity figure

—

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹109

Analyst target

No analyst coverage

—

Blended fair value₹109

What the numbers say

Investment thesis

Bull case

Strong returns on equity (100%)
Capital is working hard (ROCE 64%)
Revenue compounding 33% over 3 years
Profit growing 210% a year
Reasonably priced at 13× earnings
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

13.1Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

99.5%Strong

Above 15% is considered healthy for Indian equities

ROCE

64.2%Efficient

Above 18% means capital is working hard

Debt/Eq

1.30Elevated

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹170 Cr

P/B

2.74

EPS

₹10.66

Div Yield

—

What changed

Recent changes

Foreign investors+0.3% stake last quarter
Domestic institutions+2.3% stake last quarter
Promoters-32.30% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 13.1×

Growth

Strong

+33% rev CAGR

Profitability

Excellent

99.5% ROE

Financial health

Leveraged

D/E 1.30

Momentum

N/A

No technicals

Today

Trading activity

Delivery %81.0%

Turnover₹29.32L Cr

Trades13

VWAP₹139.62

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+33.1%

—

10Y

—

Profit

+209.7%

—

10Y

—

EPS

—

10Y

—

Profile

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 79.0%
Debtor days have improved from 62.2 to 39.2 days.

Watch-outs

Cons

Working capital days have increased from 68.4 days to 135 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 May 2026

Promoters trimmed their stake by 32.30 pts; foreign investors bought 0.29 pts; domestic institutions added 2.31 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

68%

Promoter

Promoters

67.7%-32.30

Public

21.4%+21.38

FII / FPI

0.3%+0.29

DII

2.3%+2.31

Others

8.3%

Total shareholders

1,195+1,195 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter67.70%

FII0.29%

DII2.31%

Public21.38%

Others8.32%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions